NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, has undertaken an overnight marketed offering of units.
Each unit will consist of one common share and one-half of one warrant, with
each whole warrant entitling the holder to acquire one common share for a period
of time following the closing of the offering. Prior to the offering,
Immunovaccine had 63,505,152 common shares issued and outstanding.


The offering is to be effected in each of the Canadian provinces of British
Columbia, Alberta, Ontario and Nova Scotia by way of a prospectus supplement
(the "Supplement") to Immunovaccine's base shelf prospectus of August 27, 2012
(the "Prospectus"). The number of units to be distributed, the price of each
unit, the exercise price of each whole warrant, and the exercise period for the
warrants will be determined in context of the market with final terms to be
determined at the time of pricing. Byron Capital Markets Ltd. is serving as
agent for the offering (the "Agent"), and Bloom Burton & Co. Inc. is acting as a
selling firm appointed by the Agent with respect to the offering.


The terms of the offering will be described in the Supplement which is expected
to be filed with securities regulatory authorities following the pricing of the
offering. The offering is subject to execution of an agency agreement with the
Agent. The transaction is scheduled to close on or about February 13, 2013,
subject to satisfaction of customary closing conditions, including the receipt
of all necessary regulatory and stock exchange approvals.


The securities described herein have not been, and will not be, registered under
the United States Securities Act of 1933, as amended (the "U.S. Securities
Act"), or any state securities laws, and accordingly, may not be offered or sold
within the United States except in compliance with the registration requirements
of the U.S. Securities Act and applicable state securities requirements or
pursuant to exemptions therefrom. This press release does not constitute an
offer to sell or a solicitation to buy any securities in any jurisdiction.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the offering,
is forward-looking information. Forward-looking statements are based on the
estimates and opinions of management on the date the statements are made.
However, they should not be regarded as a representation that any of the plans
will be achieved. Actual results may differ materially from those set forth in
this press release due to risks relating to the offering, including those risks
identified by the company in the Prospectus as supplemented by the Supplement,
and risks affecting the company, including access to capital, the successful
completion of clinical trials and receipt of all regulatory approvals.
Immunovaccine Inc. assumes no responsibility to update forward-looking
statements in this press release except as required by law. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
(902) 492-1819
kstephens@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com


Vida Strategic Partners (investors)
Stephanie Diaz
(415) 675-7401
sdiaz@vidasp.com


Brisco Capital Partners (Canadian investors)
Scott Koyich
(403) 262-9888
skoyich@briscocapital.com